Johnson & Johnson's McNeil Consumer Healthcare officially resumed commercial production of over-the-counter meds at its Fort Washington, Pennsylvania plant, which temporarily shut down five years ago following a series of high-profile product recalls.
Following a lengthy series of recalls involving millions of product packages, McNeil had suspended manufacturing at its Fort Washington location -- the drugmaker's primary Tylenol and OTC manufacturing site.
The resumption of manufacturing was delayed several years while McNeil complied with the terms of a consent decree it signed with the FDA in March 2011.
McNeil says it recently had a successful FDA inspection at the site, after spending over $100 million on plant improvements.
Read the Philadelphia Biz Journal article